Kings Path Partners LLC Cuts Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Kings Path Partners LLC decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 12.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,008 shares of the medical instruments supplier’s stock after selling 2,584 shares during the quarter. LeMaitre Vascular comprises about 0.7% of Kings Path Partners LLC’s investment portfolio, making the stock its 27th biggest holding. Kings Path Partners LLC owned about 0.08% of LeMaitre Vascular worth $1,673,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the stock. Driehaus Capital Management LLC raised its position in shares of LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. F M Investments LLC bought a new position in shares of LeMaitre Vascular in the second quarter worth approximately $7,443,000. Congress Asset Management Co. MA grew its holdings in shares of LeMaitre Vascular by 17.0% during the fourth quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after buying an additional 86,293 shares during the last quarter. Nicholas Investment Partners LP bought a new stake in shares of LeMaitre Vascular during the second quarter valued at approximately $3,900,000. Finally, Janus Henderson Group PLC raised its holdings in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,275 shares of company stock worth $2,598,150 in the last three months. Insiders own 10.79% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research reaffirmed an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday, September 20th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus price target of $94.40.

LeMaitre Vascular Trading Up 1.5 %

NASDAQ LMAT opened at $90.59 on Friday. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $93.32. The stock’s 50 day moving average is $88.00 and its 200 day moving average is $80.50. The stock has a market cap of $2.03 billion, a PE ratio of 59.99, a P/E/G ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period last year, the company posted $0.37 earnings per share. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were paid a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.71%. LeMaitre Vascular’s payout ratio is currently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.